Researchers racing to develop bird flu vaccines for humans have turned to a cutting-edge technology that enabled the rapid ...

Short sellers increased their bets against the broader healthcare sector in February vs. January, and Moderna remained the ...

President Donald Trump has slashed another grant given to the National Health Institute to study vaccine hesitancy and more ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

Misinformation about vaccines has swirled online since US President Donald Trump appointed Robert F. Kennedy Jr. – who has ...

On the five-year anniversary of the Covid pandemic, a Times reporter, Apoorva Mandavilli, looks back at the success of, and ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

Vaccine skeptics have long-since leveraged the rapid roll out of mRNA vaccines to add fuel to heated arguments surrounding ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Biotechnology researchers at Rensselaer Polytechnic Institute (RPI) are working to further improve mRNA therapeutics, with ...